These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22515274)

  • 1. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.
    Chamorro AJ; Marcos M; Mirón-Canelo JA; Pastor I; González-Sarmiento R; Laso FJ
    Addict Biol; 2012 May; 17(3):505-12. PubMed ID: 22515274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
    Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
    Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
    Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
    Kim SG; Kim CM; Choi SW; Jae YM; Lee HG; Son BK; Kim JG; Choi YS; Kim HO; Kim SY; Oslin DW
    Psychopharmacology (Berl); 2009 Jan; 201(4):611-8. PubMed ID: 18795264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
    Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
    Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
    Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
    Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
    Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
    Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
    Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
    Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
    Ray LA; Hutchison KE
    Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of associations of the opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) with alcohol dependence: review and meta-analysis of retrospective controlled studies.
    Kong X; Deng H; Gong S; Alston T; Kong Y; Wang J
    BMC Med Genet; 2017 Oct; 18(1):120. PubMed ID: 29070014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
    Setiawan E; Pihl RO; Benkelfat C; Leyton M
    Pharmacogenomics; 2012 Jul; 13(10):1161-72. PubMed ID: 22909206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.
    Oslin DW; Berrettini W; Kranzler HR; Pettinati H; Gelernter J; Volpicelli JR; O'Brien CP
    Neuropsychopharmacology; 2003 Aug; 28(8):1546-52. PubMed ID: 12813472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
    Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
    Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The μ-opioid receptor and treatment response to naltrexone.
    Thorsell A
    Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
    Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
    JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences in the genetic risk for alcohol dependence--the results of a pharmacogenetic study in Korean alcoholics.
    Kim SG
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2009 Dec; 44(6):680-5. PubMed ID: 20077761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.
    Jonas DE; Amick HR; Feltner C; Wines R; Shanahan E; Rowe CJ; Garbutt JC
    Pharmacogenomics; 2014 Sep; 15(13):1687-700. PubMed ID: 25410894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
    Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
    Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
    Lin Y; Kranzler HR; Farrer LA; Xu H; Henderson DC; Zhang H
    Pharmacogenomics J; 2020 Oct; 20(5):672-680. PubMed ID: 32029903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus.
    Barr CS; Chen SA; Schwandt ML; Lindell SG; Sun H; Suomi SJ; Heilig M
    Biol Psychiatry; 2010 Jan; 67(1):78-80. PubMed ID: 19748082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.